Abstracts
Case Report on Proximal Modular “Dual Press Design”
Case Report on Proximal Modular “Dual Press Design”
Timothy McTighe, PhD (hc)
 
Intraoperative Techniques in Using Proximal Modular Stems
Intraoperative Techniques in Using Proximal Modular Stems
Thomas Tkach, MD
 
A Novel Approach to Reduction of Wear In THA
A Novel Approach to Reduction of Wear In THA
Richard Treharne, PhD, MBA
 
Proximal Modular Stem Design “Dual Press” With a Dual-Tapered “K2” Trapezoid Stems
Proximal Modular Stem Design “Dual Press” With a Dual-Tapered “K2” Trapezoid Stems
Kristaps J. Keggi, MD
 
A New Approach To Neck Sparing THA Stem
A New Approach To Neck Sparing THA Stem
Timothy McTighe, PhD (hc)
 
The Role of Modularity in Primary THA - Is There One?
The Role of Modularity in Primary THA - Is There One?
Louis Keppler, MD
 
Target Restoration of Hip Mechanics in THA
Target Restoration of Hip Mechanics in THA
Tom Tkach, MD
 
Dabigatran Etexilate Is Effective And Safe For The Extended Prevention Of Venous Thromboembolism Following Total Hip Replacement
Dabigatran Etexilate Is Effective And Safe For The Extended Prevention Of Venous Thromboembolism Following Total Hip Replacement
BI Eriksson, OE Dahl, N Rosencher, et al.
 
Pharmacokinetics (Pk) And Pharmacodynamics (Pd) Of Rivaroxaban: A Comparison Of Once- And Twice-Daily Dosing In Patients Undergoing Total Hip Replacement (Thr)
Pharmacokinetics (Pk) And Pharmacodynamics (Pd) Of Rivaroxaban: A Comparison Of Once- And Twice-Daily Dosing In Patients Undergoing Total Hip Replacement (Thr)
BI Eriksson, F Misselwitz, W Mueck
 
Dabigatran Etexilate Versus Enoxaparin In Preventing Venous Thromboembolism Following Total Knee Arthroplasty
Dabigatran Etexilate Versus Enoxaparin In Preventing Venous Thromboembolism Following Total Knee Arthroplasty
RJ Friedman, JA Caprini, PC Comp, BL Davidson, et al
 
Apixaban, An Oral Direct Factor Xa Inhibitor: Multiple-Dose Safety, Pharmacokinetics, And Pharmacodynamics In Healthy Subjects
Apixaban, An Oral Direct Factor Xa Inhibitor: Multiple-Dose Safety, Pharmacokinetics, And Pharmacodynamics In Healthy Subjects
C Frost, Z Yu, K Moore, et al.
 
Apixaban, An Oral Direct, Factor Xa Inhibitor: Single-Dose Safety, Pharmacokinetics And Pharmacodynamics In Healthy Subjects
Apixaban, An Oral Direct, Factor Xa Inhibitor: Single-Dose Safety, Pharmacokinetics And Pharmacodynamics In Healthy Subjects
C Frost, Z Yu, S Nepal, R Mosqueda-Garcia, A Shenker
 
Effect Of Hepatic Impairment On The Pharmacokinetics, Pharmacodynamics And Tolerability Of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor
Effect Of Hepatic Impairment On The Pharmacokinetics, Pharmacodynamics And Tolerability Of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor
A Halabi, D Kubitza, M Zuehlsdorf, et al.
 
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Has No Clinically Relevant Interaction With Acetylsalicylic Acid Or Naproxen
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Has No Clinically Relevant Interaction With Acetylsalicylic Acid Or Naproxen
D Kubitza, M Becka, W Mueck, M Zuehlsdorf
 
The Effect Of Age And Gender On The Pharmacology And Safety Of The Oral, Direct Factor Xa Inhibitor Rivaroxaban
The Effect Of Age And Gender On The Pharmacology And Safety Of The Oral, Direct Factor Xa Inhibitor Rivaroxaban
D Kubitza, M Becka, W Mueck, M Zuehlsdorf
 
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor For The Prevention Of Venous Thromboembolism In Total Knee Replacement Surgery – Results Of The Record 3 Study
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor For The Prevention Of Venous Thromboembolism In Total Knee Replacement Surgery – Results Of The Record 3 Study
MR Lassen, AG Turpie, N Rosencher, et al.
 
Inhibition Of Measured Thrombin Generation In Human Plasma By Apixaban: A Predictive Mathematical Model Based On Experimentally Determined Rate Constants
Inhibition Of Measured Thrombin Generation In Human Plasma By Apixaban: A Predictive Mathematical Model Based On Experimentally Determined Rate Constants
JM Luettgen, Z Wang, DA Seiffert, et al.
 
Three Different Patterns Of Calibrated Automated Thrombogram Obtained With Hirudin, Melagatran, Dabigatran, Argatroban, Fondaparinux And Danaparoïd
Three Different Patterns Of Calibrated Automated Thrombogram Obtained With Hirudin, Melagatran, Dabigatran, Argatroban, Fondaparinux And Danaparoïd
MM Samama, L Le Flem, C Guinet, F Depasse
 
Coadministration Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Atorvastatin Has Little Impact On The Pharmacokinetics And Pharmacodynamics Of Either Drug
Coadministration Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Atorvastatin Has Little Impact On The Pharmacokinetics And Pharmacodynamics Of Either Drug
J Stangier, H Stähle, K Rathgen, K Reseski, T Körnicke
 
No Interaction Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Digoxin
No Interaction Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Digoxin
J Stangier, H Stähle, K Rathgen, K Reseski, T Körnicke
 
Pharmacokinetics And Pharmacodynamics Of Dabigatran Etexilate In Subjects With Moderate Hepatic Impairment
Pharmacokinetics And Pharmacodynamics Of Dabigatran Etexilate In Subjects With Moderate Hepatic Impairment
J Stangier, K Rathgen, H Stähle, K Shakeri-Nejad
 
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Binds Rapidly To Factor Xa
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Binds Rapidly To Factor Xa
A Tersteegen, N Burkhardt
 
Recombinant Factor Viia Partially Reverses The Anticoagulant Effect Of High-Dose Rivaroxaban – A Novel, Oral, Direct Factor Xa Inhibitor – In Rats
Recombinant Factor Viia Partially Reverses The Anticoagulant Effect Of High-Dose Rivaroxaban – A Novel, Oral, Direct Factor Xa Inhibitor – In Rats
H Tinel, J Huetter, E Perzborn